

ORIGINAL ARTICLE

Variations of CHROMagar Acinetobacter to detect imipenem-resistant *Acinetobacter baumannii*–*calcoaceticus* complex

ALICE BARSOUMIAN¹, TATJANA CALVANO¹, ANA E. MARKELZ¹,
RYAN CASSIDY², CLINTON K. MURRAY^{1,3}, MIRIAM L. BECKIUS⁴,
KATRIN MENDE^{1,5} & KEVIN S. AKERS^{1,3}

From the ¹Infectious Disease Service, San Antonio Military Medical Center, Fort Sam Houston, Texas, ²University of Texas, Austin, Texas, ³Uniformed Services University of the Health Sciences, Bethesda, Maryland, ⁴Department of Clinical Investigation, San Antonio Military Medical Center, Fort Sam Houston, Texas, and ⁵Infectious Disease Clinical Research Program, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA

Abstract

Background: *Acinetobacter baumannii*–*calcoaceticus* complex (ABC) isolates are often multidrug-resistant, including to carbapenems. Chromogenic media can facilitate the rapid detection of Gram-negative bacteria, often with the addition of supplements to a base chromogenic medium to detect resistance. We examined various combinations of available media to detect imipenem resistance among 107 ABC clinical isolates. **Methods:** CHROMagar Orientation, CHROMagar KPC, and CHROMagar Acinetobacter, by itself, with Acinetobacter supplement, with KPC supplement, or CHROMagar Acinetobacter with increasing concentrations (1, 2.5, and 5 ml/l) of a new CR102 supplement, were examined. **Results:** Sensitivity for the detection of isolates was high (>98%) for all formulations. Specificity was high for CHROMagar Acinetobacter with 2.5 ml/l and 5 ml/l of the CR102 supplement, at 95.3% and 97.7%, respectively, with positive predictive values of 97% and 98.5%. Negative predictive values of these 2 formulations were 100%. **Conclusions:** CHROMagar Acinetobacter with the addition of the CR102 supplement at 2.5 ml/l and 5 ml/l is highly sensitive and specific for the detection of imipenem-resistant ABC, and may be useful for the rapid detection of imipenem-resistant ABC in clinical samples.

Keywords: *Acinetobacter baumannii*–*calcoaceticus* complex, MDR, CHROMagar, carbapenem

Introduction

Acinetobacter baumannii–*calcoaceticus* complex (ABC) is a prevalent multidrug-resistant (MDR) nosocomial pathogen with increasing carbapenem resistance, presenting significant treatment and infection control challenges [1–5]. Nosocomial outbreaks of ABC can lead to prolonged hospitalization and possibly increased mortality rates [4]. ABC was the leading MDR organism recovered over a 6-y period in a military burn center [6], and is an important pathogen with multiple resistance mechanisms to antimicrobial agents [2,3,7–9]. As a means of interrupting nosocomial transmission, rapid detection methods providing

early identification of MDR ABC would be helpful to provide appropriate, timely treatment and implement adequate infection control measures [3,10].

Chromogenic selective media have been used for the early detection of multiple organisms. These media aid in the rapid detection of pathogens, providing the opportunity for earlier treatment and to guide infection control measures. Chromogenic media are commercially available for the detection of methicillin-resistant *Staphylococcus aureus* (MRSA) [11–13], vancomycin-resistant *Enterococcus* spp. [14], extended-spectrum beta-lactamase (ESBL)-producing Gram-negative pathogens [15,16], and

The opinions or assertions contained herein are the private views of the authors and are not to be construed as official or reflecting the views of the Department of the Army, Department of the Air Force, Department of Defense or the US Government. This work was prepared as part of their official duties and, as such, there is not copyright to be transferred.

Correspondence: K. S. Akers, Infectious Disease Service, MCHE-MDI, San Antonio Military Medical Center, Brooke Army Medical Center, 3551 Roger Brooke Drive, Fort Sam Houston, TX 78234, USA. Tel: +1 210 916 5554. Fax: +1 210 916 5900. E-mail: kevin.akers@us.army.mil

(Received 30 October 2012; accepted 10 December 2012)

Candida species [17]. In its initial formulations, CHROMagar Acinetobacter (CHROMagar, Paris, France) showed some promise in the identification of a single clone in the setting of an outbreak [18], but was found to be non-specific for the detection of imipenem-resistant ABC [19,20]. Recently, the addition of a proprietary supplement from a separate medium, CHROMagar KPC, intended to suppress the growth of carbapenem-susceptible bacteria, was shown to improve the specificity of this CHROMagar Acinetobacter using a limited number of ABC study isolates [21]. CHROMagar KPC reliably distinguishes carbapenem-resistant Enterobacteriaceae carrying the KPC gene [22], but was subsequently shown to be less sensitive for the detection of isolates having a lower level of carbapenem resistance [23].

We first examined whether we could replicate the improved diagnostic utility of CHROMagar Acinetobacter base plus Acinetobacter supplement with the KPC supplement for detection of imipenem-resistant isolates compared to non-supplemented CHROMagar Orientation base medium, CHROMagar Acinetobacter base and CHROMagar KPC using a larger number of well-characterized ABC clinical isolates. We then examined CHROMagar Acinetobacter base supplemented with CR102, a proprietary agent designed to improve the selective recovery of carbapenem-resistant organisms, and included in the final medium composition [24], for its ability to detect imipenem-resistant ABC.

Materials and methods

Clinical Acinetobacter isolates

One hundred and seven single-patient ABC isolates from blood and wound infections from 2006 to 2008 were studied. All isolates had previously been characterized by pulsed-field gel electrophoresis (PFGE) typing and had known carbapenem susceptibilities [25,26]. We chose imipenem as the representative carbapenem since it had the greatest activity against

these isolates according to Clinical and Laboratory Standards Institute (CLSI) broth microdilution testing. CLSI minimum inhibitory concentration (MIC) breakpoints for imipenem against *A. baumannii* were used: susceptible ≤ 4 $\mu\text{g/ml}$, intermediate 8 $\mu\text{g/ml}$, and resistant ≥ 16 $\mu\text{g/ml}$ [27]. To extend the applicability of study results to Europe, interpretive criteria of the European Committee on Antimicrobial Susceptibility Testing (EUCAST) for imipenem were also applied: susceptible ≤ 2 $\mu\text{g/ml}$ and resistant > 8 $\mu\text{g/ml}$ [28].

Control isolates

Twenty-four clinical and reference isolates of Gram-negative and Gram-positive bacteria, including ATCC strains of *A. baumannii* (ATCC 19606), *Acinetobacter lwoffii* (ATCC 15309), and *A. calcoaceticus* (ATCC 23055, ATCC 51432) were tested. Gram-negative control isolates were characterized using Phoenix NMIC/ID 121 or 123 panels (Becton, Dickinson and Co., Franklin Lakes, NJ, USA) and VITEK-2/GN25 cards (bioMérieux, NC, USA) to determine imipenem susceptibilities. Susceptibilities of all Gram-positive bacterial isolates were determined by Etest (AB bioMérieux, Solna, Sweden).

Preparation of media

CHROMagar Orientation (CA/O) base medium and CHROMagar Acinetobacter (CA/ABC) base medium were prepared from dehydrated powder in accordance with the manufacturer's instructions. CHROMagar KPC (CA/O + KPC) was prepared as intended by adding the KPC supplement to the dehydrated CA/O base medium. CHROMagar Acinetobacter plus Acinetobacter supplement (CA/ABC + ABC) and CHROMagar Acinetobacter plus KPC supplement (CA/ABC + ABC + KPC) were also prepared in the same manner. In the second phase of the experiment, CA/ABC was supplemented with the CR102 supplement in increasing concentrations (1 ml/l (CA/ABC + CR102-1), 2.5 ml/l

Table I. Description of tested media.

Tested media	Chromogenic base media	Supplement	Additional supplement
CA/O	CHROMagar Orientation	N/A	N/A
CA/ABC	CHROMagar Acinetobacter	N/A	N/A
CA/ABC + ABC	CHROMagar Acinetobacter	Acinetobacter	N/A
CA/ABC + ABC + KPC	CHROMagar Acinetobacter	Acinetobacter	KPC
CA/O + KPC	CHROMagar Orientation	KPC	N/A
CA/ABC + CR102-1	CHROMagar Acinetobacter	1 ml/l CR102	N/A
CA/ABC + CR102-2	CHROMagar Acinetobacter	2.5 ml/l CR102	N/A
CA/ABC + CR102-3	CHROMagar Acinetobacter	5 ml/l CR102	N/A

N/A, Not applicable.

(CA/ABC + CR102-2), and 5 ml/l (CA/ABC + CR102-3)), in accordance with the manufacturer's instructions (Table I). Media were refrigerated, protected from the light, and used within 35 days, as recommended.

Inoculation of media

Bacterial isolates stored at -80°C were passed twice on tryptic soy agar (TSA) containing 5% sheep's blood (REMEL, Lenexa, KS) and incubated at 35°C for 24 h. Saline bacterial suspensions containing approximately 10^8 CFU/ml were prepared using a 0.5 McFarland standard. A 50- μl aliquot of appropriate dilutions, resulting in approximately 50 CFU of each sample, was inoculated onto chromogenic agar plates and incubated at 35°C for 24 h. The color of growing colonies was matched to an artist's color wheel (The ColorWheel Company, Philomath, OR, USA) by 2 independent observers. A single run of CA/O, CA/O + KPC, CA/ABC, CA/ABC + ABC, and CA/ABC + ABC + KPC, was performed to assess the ABC and KPC supplements. For the second phase, a single run of CA/ABC as the control, CA/ABC + CR102-1, CA/ABC + CR102-2, and CA/ABC + CR102-3 was performed.

Polymicrobial cultures

The agar formulations were also tested to assess their ability to distinguish *Acinetobacter* from polymicrobial inoculae. Thirteen plates of each medium were prepared. Twenty control isolates including clinical and reference strains, and 4 different, randomly selected clinical ABC isolates were selected in groups of 3 isolates and suspended in saline in equal proportions. A 50- μl aliquot of sample, yielding approximately 50 CFU of mixed species, was applied to the agar plates by a person not responsible for data collection or interpretation. These were also plated on TSA for colony counts and confirmation of species present. After overnight incubation at 35°C , the plates were scored for ABC growth and color independently by 2 observers blinded to the composition of the inoculae and the agar formulations.

Statistical methods

For ABC isolates, sensitivity and specificity of the media for the detection of imipenem-resistant isolates (growth of isolates at intended red color) were calculated, as well as positive predictive values (PPV) and negative predictive values (NPV).

Table II. Growth of clinical *Acinetobacter baumannii*-calcoaceticus complex isolates on tested media.

Clinical isolates (number)	Number (%) of isolates that grew with the appropriate appearance on:							
	CA/O + KPC	CA/O	CA/ABC ^a	CA/ABC + ABC	CA/ABC + ABC + KPC	CA/ABC + CR102-1	CA/ABC + CR102-2	CA/ABC + CR102-3
<i>Acinetobacter baumannii</i> -calcoaceticus complex (107)	99 (93%)	107 (100%)	107 (100%)	106 (99%)	97 (91%)	87 (81%)	66 (62%)	65 (61%)
Imipenem-susceptible (40) (18 PFTs)	33 (80%)	40 (100%)	40 (100%)	39 (98%)	32 (78%)	20 (50%)	0 (0%)	0 (0%)
Imipenem-intermediate (3) (3 PFTs)	3 (100%)	3 (100%)	3 (100%)	3 (100%)	3 (100%)	3 (100%)	2 (66%)	1 (33%)
Imipenem-resistant (64) (9 PFTs)	64 (100%)	64 (100%)	64 (100%)	64 (100%)	63 (98%)	64 (100%)	64 (100%)	64 (100%)

PFT, pulsed-field type.

^aCA/ABC was run during each phase of the experiment and results were identical during each run.

Table III. Sensitivity, specificity, positive predictive value, and negative predictive value of CHROMagar formulations for the identification of imipenem-resistant *Acinetobacter baumannii*-calcoaceticus complex.

	CA/O	CA/O + KPC	CA/ABC	CA/ABC + ABC	CA/ABC + ABC + KPC	CA/ABC + CR102-1	CA/ABC + CR102-2	CA/ABC + CR102-3
Sensitivity	100%	100%	100%	100%	98%	100%	100%	100%
Specificity	0%	0%	0%	2.3%	20%	46.5%	95.3%	97.7%
PPV	60.4%	64.6%	60.4%	60.4%	64%	73.6%	97.0%	98.5%
NPV	100%	100%	100%	100%	88.9%	100%	100%	100%

PPV, positive predictive value; NPV, negative predictive value.

Results

Clinical Acinetobacter isolates

One hundred and seven (100%) of the *Acinetobacter* clinical isolates produced red colonies on CA-ABC. Using CLSI interpretive criteria, 64 were resistant (IMP-R), 40 were susceptible, and 3 were intermediate to imipenem. Ninety-three percent of all isolates grew on CA/O + KPC, and 91% grew on CA/ABC + ABC + KPC (including susceptible isolates). None of the imipenem-susceptible isolates grew on CA/ABC + CR102-2 and CA/ABC + CR102-3 (Table II). Applying CLSI criteria, sensitivity for the detection of IMP-R isolates was >98% for all medium formulations, while specificity was highest with increasing CR102 concentration (Table III, Figure 1). CA/ABC + CR102-3 also had the highest PPV, while NPV was high for all the media. Applying EUCAST susceptibility criteria, sensitivities and specificities of the media in the second run were: CA/ABC 100%/0%, CA/ABC + CR102-1 100%/52.5%, CA/ABC + CR102-2 97%/100%, and CA/ABC + CR102-3 95.5%/100%.

Control isolates

Out of 24 control isolates, only 1 reference isolate, *A. calcoaceticus* ATCC 51432, demonstrated growth of red colonies on the majority of the media tested, but was suppressed on CA/ABC + CR102-2 and CA/ABC + CR102-3. The other reference *Acinetobacter* isolates, with retained susceptibility to imipenem, did not grow on any media (Table IV). Growth of the other control organisms was infrequently noted, and no other organisms grew on media supplemented with CR102.

Polymicrobial cultures

In the first blinded reading trial, identification of ABC in mixed cultures had a sensitivity/specificity of 100%/60% on CA/O, 80%/67% on CA/O + KPC, 90%/67% on CA/ABC, 90%/67% on CA/ABC + ABC, and 80%/100% on CA/ABC + ABC + KPC. One imipenem-susceptible clinical ABC isolate randomly selected for this portion of the study did not grow on these media in pure culture. In the second




Figure 1. Colonies of an imipenem-intermediate (MIC 8 µg/ml) clinical isolate of *Acinetobacter baumannii*-calcoaceticus complex showing robust growth on CA/ABC (A: CHROMagar *Acinetobacter*), decreasing growth with increasing concentrations of CR102 supplement (B: CA/ABC + CR102-1, 1 ml/l CR102; C: CA/ABC + CR102-2, 2.5 ml/l CR102; D: CA/ABC + CR102-3, 5 ml/l CR102).

Table IV. Colony color of the control isolates used for testing the experimental media.

Isolate	Imipenem susceptibility (by CLSI)	CA/O	CA/O + KPC	CA/ABC	CA/AB + ABC	CA/ABC + ABC + KPC	CA/ABC + GR102-1	CA/ABC + GR102-2	CA/ABC + CR102-3
<i>Acinetobacter baumannii</i> ATCC 19606	S	White	NG	NG	NG	NG	NG	NG	NG
<i>Acinetobacter calcoaceticus</i> ATCC 23055	S	NG	NG	NG	NG	NG	NG	NG	NG
<i>A. calcoaceticus</i> ATCC 51432	R	White	Translucent	Red	Red	Red	Red	NG	NG
<i>Acinetobacter lwoffii</i> ATCC 15309	S	White	NG	NG	NG	NG	NG	NG	NG
<i>Citrobacter freundii</i> 971	S	Blue-violet	Red-violet	NG	NG	NG	NG	NG	NG
<i>Enterobacter cloacae</i> , clinical isolate 1	I	Red-violet	Red-violet	NG	NG	NG	NG	NG	NG
<i>E. cloacae</i> 973	S	Blue	NG	Blue	Blue	NG	NG	NG	NG
<i>E. cloacae</i> , clinical isolate 2	S	Blue	NG	White, red ^b	Blue-violet	NG	NG	NG	NG
<i>Escherichia coli</i> , clinical isolate 1	R	Green, blue-green ^c	Red-violet	NG	NG	NG	NG	NG	NG
<i>E. coli</i> , clinical isolate 2	S	Red-violet	NG	NG	NG	NG	NG	NG	NG
<i>E. coli</i> ATCC 25922	S	Red-violet	NG	NG	NG	NG	NG	NG	NG
<i>E. coli</i> ATCC 35218	S	Red-violet	NG	NG	NG	NG	NG	NG	NG
<i>Enterococcus faecalis</i> ATCC 29212	2 µg/ml ^a	Blue-green	NG	NG	NG	NG	NG	NG	NG
<i>E. faecalis</i> ATCC 51299	3 µg/ml ^a	Green	NG	NG	NG	NG	NG	NG	NG
<i>Klebsiella pneumoniae</i> 3142	S	Blue	NG	NG	NG	NG	NG	NG	NG
<i>K. pneumoniae</i> KPC-2	I	Blue	Blue-green	Blue, white ^b	Blue-green	Blue	NG	NG	NG
<i>K. pneumoniae</i> , clinical isolate	S	Blue	NG	Blue	Blue	NG	NG	NG	NG
<i>Pseudomonas aeruginosa</i> , clinical isolate 1	S	White, blue ^b	NG	NG	NG	NG	NG	NG	NG
<i>P. aeruginosa</i> , clinical isolate 2	R	White	Translucent	NG	NG	NG	NG	NG	NG
<i>P. aeruginosa</i> ATCC 27853	S	White	NG	NG	NG	NG	NG	NG	NG
<i>Staphylococcus aureus</i> , clinical isolate (MRSA)	N/A	White	NG	NG	NG	NG	NG	NG	NG
<i>S. aureus</i> ATCC 25923	S	White	NG	NG	NG	NG	NG	NG	NG
<i>S. aureus</i> ATCC 29213	S	White	NG	NG	NG	NG	NG	NG	NG
<i>Serratia marcescens</i> 972	S	Blue-green, white ^b	Translucent	NG	NG	NG	NG	NG	NG

CLSI, Clinical and Laboratory Standards Institute; MRSA, methicillin-resistant *Staphylococcus aureus*; N/A, not available; NG, no growth.^aMinimum inhibitory concentration (MIC).^bDenotes more than 1 color of colony growth.^cDenotes inter-observer variability.

blinded reading trial, all agars tested (CA/ABC, CA/ABC + CR102-1, CA/ABC + CR102-2, CA/ABC + CR102-3), had sensitivities and specificities of 100% for all tested media. Examples of polymicrobial plates are shown in Figure 2.

Discussion

The development of a reliable medium to more rapidly detect MDR ABC would be helpful to provide a timely and appropriate clinical and infection control response. The goal of this study was to determine the diagnostic characteristics of various CHROMagar formulations using a library of genetically heterogeneous isolates with known carbapenem resistance phenotypes. In this study, we demonstrated that CHROMagar *Acinetobacter* without additional supplement was not specific for imipenem-resistant isolates, as previously described [19,20]. We also found CHROMagar KPC to have insufficient specificity for the detection of imipenem-resistant ABC. In a recent study of 7 *Acinetobacter* isolates (5 resistant and 2 susceptible to carbapenems), CHROMagar *Acinetobacter* with KPC supplement successfully differentiated carbapenem-resistant strains on 2 CHROMagar *Acinetobacter* medium formulations [21]. However, we were unable to confirm these findings using a larger selection of clinical isolates, including 40 imipenem-susceptible isolates. It is unclear by what mechanism the KPC supplement is able to improve the selection of the CHROMagar media for other uses. Of the 36 imipenem-susceptible and imipenem-intermediate *Acinetobacter* isolates that grew on CA/O + KPC and CA/

ABC + ABC + KPC, 34 were susceptible or intermediate to other carbapenems (doripenem and/or meropenem) and 6 were susceptible or intermediate to ceftazidime. This would suggest that the KPC supplement does not detect carbapenem resistance by the addition of one of these agents. Based on our findings, CHROMagar *Acinetobacter* with the addition of KPC supplement would have limited utility in detecting carbapenem-resistant ABC.

In contrast, we found that CHROMagar *Acinetobacter* containing 2.5 ml/l or 5 ml/l (the intended concentration as per the manufacturer) of the proprietary supplement CR102 had high sensitivity and specificity for the detection of imipenem-resistant isolates of ABC, as defined by using both CLSI and EUCAST MIC breakpoints for imipenem against *A. baumannii*. These performance characteristics rival those of other chromogenic media currently available for clinical use, such as CHROMagar KPC for the detection of carbapenem-resistant *Klebsiella pneumoniae* (sensitivity/specificity of 100%/98.4%) [22], and CHROMagar MRSA used for the detection of MRSA (sensitivity/specificity > 90%) [12]. Given its high sensitivity and specificity for the chromogenic detection of imipenem-resistant ABC in this laboratory-based study, CHROMagar *Acinetobacter* with CR102 supplementation appears promising for clinical use. While these results are encouraging, and represent a significant improvement over earlier formulations of CHROMagar *Acinetobacter*, a multicenter clinical trial examining the real-time use of this medium with patient samples submitted to a clinical microbiology laboratory is required before it can be recommended for clinical use.




Figure 2. Growth of imipenem-resistant *Acinetobacter baumannii*-*calcoaceticus* complex (red colonies, MIC 32 µg/ml) and imipenem-susceptible *Enterobacter cloacae* (blue colonies, MIC ≤ 1 µg/ml) resulting from a polymicrobial inoculum. B, C and D have evidence of red colony growth consistent with imipenem-resistant *Acinetobacter baumannii*-*calcoaceticus* complex. A: CA/ABC, no supplement; B: CA/ABC + CR102-1, 1 ml/l CR102; C: CA/ABC + CR102-2, 2.5 ml/l CR102; D: CA/ABC + CR102-3, 5 ml/l CR102.

Acknowledgements

The authors gratefully acknowledge the support of the US Armed Forces Health Surveillance Center, Division of Global and Emerging Infections Surveillance and Response System Operations, and the Infectious Diseases Clinical Research Program.

Declaration of interest: Tested media and supplements were obtained from CHROMagar (Paris, France). CHROMagar had no input in study design or data analysis.

References

- [1] Maragakis LL, Perl TM. *Acinetobacter baumannii*: epidemiology, antimicrobial resistance, and treatment options. *Clin Infect Dis* 2009;46:1254–63.
- [2] Fishbain J, Peleg AY. Treatment of *Acinetobacter* infections. *Clin Infect Dis* 2010;51:79–84.
- [3] Villalón P, Valdezate S, Medina-Pascual MJ, Rubio V, Vindel A, Saez-Nieto JA. Clonal diversity of nosocomial epidemic *Acinetobacter baumannii* strains isolated in Spain. *J Clin Microbiol* 2011;49:875–82.
- [4] Garlantézec R, Bourigault C, Boles JM, Prat G, Baron R, Tonnelier JM, et al. Cost-analysis of an intensive care unit closure due to an imipenem-resistant oxa-23 *Acinetobacter baumannii* outbreak. *J Hosp Infect* 2011;72:174–5.
- [5] Karah N, Haldorsen B, Hermansen NO, Tveten Y, Ragnhildstveit E, Skutlaberg DH, et al. Emergence of OXA-carbapenemase and 16S rRNA methylase-producing international clones of *Acinetobacter baumannii* in Norway. *J Med Microbiol* 2011;60:515–21.
- [6] Keen EF 3rd, Robinson BJ, Hospenthal DR, Aldous WK, Wolf SE, Chung KK, et al. Prevalence of multidrug-resistant organisms recovered at a military burn center. *Burns* 2010;36:819–25.
- [7] Albrecht MC, Griffith ME, Murray CK, Chung KK, Horvath EE, Ward JA, et al. Impact of *Acinetobacter* infection on the mortality of burn patients. *J Am Coll Surg* 2006;203:546–50.
- [8] Chuang YC, Sheng WH, Li SY, Lin YC, Wang JT, Chen YC, et al. Influence of genospecies of *Acinetobacter baumannii* complex on clinical outcomes of patients with *Acinetobacter* bacteremia. *Clin Infect Dis* 2011;52:352–60.
- [9] Coyne S, Courvalin P, Périchon B. Efflux-mediated antibiotic resistance in *Acinetobacter* spp. *Antimicrob Agents Chemother* 2011;55:947–53.
- [10] Scott P, Deye G, Srinivasan A, Murray C, Moran K, Hulten E, et al. An outbreak of multidrug-resistant *Acinetobacter baumannii*-calcoaceticus complex infection in the US military health care system associated with military operations in Iraq. *Clin Infect Dis* 2007;44:1577–84.
- [11] Yang HY, Suh JT, Lee HJ. Evaluation of commercial selective agars in screening for methicillin-resistant *Staphylococcus aureus*. *Ann Clin Lab Sci* 2010;40:252–6.
- [12] Wendt C, Havill NL, Chapin KC, Boyce JM, Dickenson R, Eigner U, et al. Evaluation of a new selective medium, BD BBL CHROMagar MRSA II for detection of methicillin-resistant *Staphylococcus aureus* in different specimens. *J Clin Microbiol* 2010;48:2223–7.
- [13] Havill NL, Boyce JM. Evaluation of a new selective medium, BD BBL CHROMagar MRSA II, for detection of methicillin-resistant *Staphylococcus aureus* in stool specimens. *J Clin Microbiol* 2010;48:2228–30.
- [14] Stamper PD, Shulder S, Bekalo P, Manandhar D, Ross TL, Speser S, et al. Evaluation of BBL CHROMagar VanRE for detection of vancomycin-resistant enterococci in rectal swab specimens. *J Clin Microbiol* 2010;48:4294–7.
- [15] Saito R, Koyano S, Nagai R, Okamura N, Moriya K, Koike K. Evaluation of a chromogenic agar medium for the detection of extended-spectrum beta-lactamase-producing Enterobacteriaceae. *Lett Appl Microbiol* 2010;51:704–6.
- [16] Paniagua R, Valverde A, Coque TM, Baquero F, Cantón R. Assessment of prevalence and changing epidemiology of extended-spectrum beta-lactamase-producing Enterobacteriaceae fecal carriers using a chromogenic medium. *Diagn Microbiol Infect Dis* 2010;67:376–9.
- [17] Guzel AB, Ilkit M, Akar T, Burgut R, Demir SC. Evaluation of risk factors in patients with vulvovaginal candidiasis and the value of chromID Candida agar versus CHROMagar Candida for recovery and presumptive identification of vaginal yeast species. *Med Mycol* 2011;49:16–25.
- [18] Gordon NC, Wareham DW. Evaluation of CHROMagar *Acinetobacter* for detection of enteric carriage of multidrug-resistant *Acinetobacter baumannii* in samples from critically ill patients. *J Clin Microbiol* 2009;47:2249–51.
- [19] Akers KS, Barsoumian A, Beckius ML, Murray CK, Mende K. CHROMagar *Acinetobacter* is not selective for carbapenem-resistant *Acinetobacter baumannii*-calcoaceticus complex. *Diagn Microbiol Infect Dis* 2010;67:209–11.
- [20] Ajao AO, Robinson G, Lee MS, Ranke TD, Venezia RA, Furuno JP, et al. Comparison of culture media for detection of *Acinetobacter baumannii* in surveillance cultures of critically ill patients. *Eur J Clin Microbiol Infect Dis* 2011;30:1425–30.
- [21] Wareham DW, Gordon NC. Modifications to CHROMagar *Acinetobacter* for improved selective growth of multi-drug resistant *Acinetobacter baumannii*. *J Clin Pathol* 2011;64:164–7.
- [22] Samra Z, Bahar J, Madar-Shapiro L, Aziz N, Israel S, Bishara J. Evaluation of CHROMagar KPC for rapid detection of carbapenem-resistant Enterobacteriaceae. *J Clin Microbiol* 2008;46:3110–1.
- [23] Carrër A, Fortineau N, Nordmann P. Use of the ChromID ESBL medium for detecting carbapenemase-producing Enterobacteriaceae. *J Clin Microbiol* 2010;48:1913–4.
- [24] CHROMagar *Acinetobacter* instructions for use. CHROMagar; 2011. Available at: http://www.chromagar.com/fichiers/1304000705NT_EXT_055_V2.pdf (accessed 26 March 2012).
- [25] Akers KS, Chaney C, Barsoumian A, Beckius M, Zera W, Yu X, et al. Aminoglycoside resistance and susceptibility testing errors in *Acinetobacter baumannii*-calcoaceticus complex. *J Clin Microbiol* 2010;48:1132–8.
- [26] Markelz AE, Mende K, Murray CK, Yu X, Zera WC, Hospenthal DR, et al. Carbapenem susceptibility testing errors using three automated systems, disk diffusion, Etest, and broth microdilution and carbapenem resistance genes in isolates of *Acinetobacter baumannii*-calcoaceticus complex. *Antimicrob Agents Chemother* 2011;55:4707–11.
- [27] Cockerill FR, Wikler MA, Alder J, Dudley MN, Eliopoulos GM, et al. Performance standards for antimicrobial susceptibility testing; twenty-second informational supplement. M100-S22. Wayne, PA: Clinical and Laboratory Standards Institute; 2012.
- [28] European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters, version 2.0. EUCAST; 2012. Available at: http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/Breakpoint_table_v_2.0_1202212.pdf (accessed 26 March 2012).

Copyright of Scandinavian Journal of Infectious Diseases is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use.